|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kurokawa Y, Doki Y, Mizusawa J, Terashima
M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y,
Fukushima N, et al: Bursectomy versus omentectomy alone for
resectable gastric cancer (JCOG1001): A phase 3, open-label,
randomised controlled trial. Lancet Gastroenterol Hepatol.
3:460–468. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colvin H, Mizushima T, Eguchi H, Takiguchi
S, Doki Y and Mori M: Gastroenterological surgery in Japan: The
past, the present and the future. Ann Gastroenterol Surg. 1:5–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hashimoto T, Kurokawa Y, Mori M, et al:
Update on the Treatment of gastric cancer. JMA J. 1:40–9. 2018.
View Article : Google Scholar
|
|
5
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3, openlabel,
randomized controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartley AN and Hamilton SR: Select
biomarkers for tumors of the gastrointestinal tract: Present and
future. Arch Pathol Lab Med. 139:457–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hashimoto T, Kurokawa Y, Takahashi T,
Miyazaki Y, Tanaka K, Makino T, Yamasaki M, Nakajima K, Ikeda JI,
Mori M and Doki Y: Predictive value of MLH1 and PD-L1 expression
for prognosis and response to preoperative chemotherapy in gastric
cancer. Gastric Cancer. 22:785–792. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thompson PM, Gotoh T, Kok M, White PS and
Brodeur GM: CHD5, a new member of the chromodomain gene family, is
preferentially expressed in the nervous system. Oncogene.
22:1002–1011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okawa ER, Gotoh T, Manne J, Igarashi J,
Fujita T, Silverman KA, Xhao H, osse YP, White PS and Brodeur GM:
Expression and sequence analysis of candidates for the 1p36.31
tumor suppressor gene deleted in neuroblastomas. Oncogene.
27:803–810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kolla V, Zhuang T, Higashi M, Naraparaju K
and Brodeur GM: Role of CHD5 in human cancers: 10 years later.
Cancer Res. 74:652–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oliver SS, Musselman CA, Srinivasan R,
Svaren JP, Kutateladze TG and Denu JM: Multivalent recognition of
histone tails by the PHD fingers of CHD5. Biochemistry.
51:6534–6544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bagchi A, Papazoglu C, Wu Y, Capurso D,
Brodt M, Francis D, Bredel M, Vogel H and Mills AA: CHD5 is a tumor
suppressor at human 1p36. Cell. 128:459–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mulero-Navarro S and Esteller M: Chromatin
remodeling factor CHD5 is silenced by promoter CpG island
hypermethylation in human cancer. Epigenetics. 3:210–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baykara O, Tansarikaya M, Bulut P,
Demirkaya A and Buyru N: CHD5 is a potential tumor suppressor in
non small cell lung cancer (NSCLC). Gene. 618:65–68. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang X, Lau KK, So LK and Lam YW: CHD5 is
down-regulated through promoter hypermethylation in gastric cancer.
J Biomed Sci. 16:952009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu G, Zhu H, Zhang M and Xu J: Histone
deacetylase 3 is associated with gastric cancer cell growth via the
miR-454-mediated targeting of CHD5. Int J Mol Med. 41:155–163.
2018.PubMed/NCBI
|
|
17
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, He S, Tu Y, Ji P, Zong J, Zhang J,
Feng F, Zhao J, Gao G and Zhang Y: Downregulation of chromatin
remodeling factor CHD5 is associated with a poor prognosis in human
glioma. J Clin Neurosci. 20:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hall WA, Petrova AV, Colbert LE, Hardy CW,
Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K,
et al: Low CHD5 expression activates the DNA damage response and
predicts poor outcome in patients undergoing adjuvant therapy for
resected pancreatic cancer. Oncogene. 33:5450–5456. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamamoto M, Takahashi T, Serada S, Sugase
T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima
K, et al: Overexpression of leucine-rich α2-glycoprotein-1 is a
prognostic marker and enhances tumor migration in gastric cancer.
Cancer Sci. 108:2052–2060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garcia I, Mayol G, Rodriguez E, Suñol M,
Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde
AR, et al: Expression of the neuron-specific protein CHD5 is an
independent marker of outcome in neuroblastoma. Mol Cancer.
9:2772010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao R, Yan Q, Lv J, Huang H, Zheng W,
Zhang B and Ma W: CHD5, a tumor suppressor that is epigenetically
silenced in lung cancer. Lung Cance. 76:324–331. 2012. View Article : Google Scholar
|
|
23
|
Qu Y, Dang S and Hou P: Gene methylation
in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang
Z, Luo A, Sun X, Fu L and Dong JT: Chromodomain helicase DNA
binding protein 5 plays a tumor suppressor role in human breast
cancer. Breast Cancer Res. 14:R732012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fatemi M, Paul TA, Brodeur GM, Shokrani B,
Brim H and Ashktorab H: Epigenetic silencing of CHD5, a novel
tumor-suppressor gene, occurs in early colorectal cancer stages.
Cancer. 120:172–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong RR, Chan LK, Tsang TP, Lee CW, Cheung
TH, Yim SF, Siu NS, Lee SN, Yu MY, Chim SS, et al: CHD5
downregulation associated with poor prognosis in epithelial ovarian
cancer. Gynecol Obstet Invest. 72:203–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujita T, Igarashi J, Okawa ER, Gotoh T,
Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, et al: CHD5,
a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J
Natl Cancer Inst. 100:940–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du Z, Li L, Huang X, Jin J, Huang S, Zhang
Q and Tao Q: The epigenetic modifier CHD5 functions as a novel
tumor suppressor for renal cell carcinoma and is predominantly
inactivated by promoter CpG methylation. Oncotarget.
7:21618–216130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Naraparaju K, Kolla V, Zhuang T, Higashi
M, Iyer R, Kolla S, Okawa ER, Blobel GA and Brodeur GM: Role of
microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene
in neuroblastomas. Oncotarget. 7:15977–15985. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie CR, Li Z, Sun HG, Wang FQ, Sun Y, Zhao
WX, Zhang S, Zhao WX, Wang XM and Yin ZY: Mutual regulation between
CHD5 and EZH2 in hepatocellular carcinoma. Oncotarget.
6:40940–40952. 2015. View Article : Google Scholar : PubMed/NCBI
|
